Luminex Corporation Second Quarter Earnings Release Scheduled for July 25, 2007
July 23 2007 - 10:00AM
PR Newswire (US)
AUSTIN, Texas, July 11 /PRNewswire-FirstCall/ -- Luminex
Corporation (NASDAQ:LMNX) today announced that it expects to report
second quarter results on Wednesday, July 25, 2007. Results are
scheduled for release after the close of trading. Management will
hold a conference call to discuss the operating highlights and
financial results for the first quarter ended June 30, 2007, on
July 26, 2007, at 8:00 a.m. Eastern time. The conference call will
be webcast live and will be accompanied by a slide presentation,
both of which may be accessed at Luminex Corporation's website at
http://www.luminexcorp.com/. Simply log on to the web at the
address above, go to the Company section and access the Investor
Relations link. Please go to the website at least 15 minutes prior
to the call to register, download and install any necessary
audio/video software. If you are unable to participate during the
live webcast, the call and slides will be archived for one year on
the website using the 'replay' link. The use of pop-up blocking
software may impair your ability to view webcasts. If you use this
software, press and hold the CTRL key when you click on the
Register button. Please contact your IT group if you are unable to
override this feature. Unauthorized recording or downloading of
this event is not permitted. Luminex Corporation develops,
manufactures and markets proprietary biological testing
technologies with applications throughout the life sciences
industry. The Company's xMAP(R) system is an open-architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics research markets.
The Company's xMAP(R) technology is sold worldwide and is in use in
leading research laboratories as well as major pharmaceutical,
diagnostic and biotechnology companies. Further information on
Luminex Corporation or xMAP(R) can be obtained on the Internet at
http://www.luminexcorp.com/. Statements made in this release that
express Luminex's or management's intentions, plans, beliefs,
expectations or predictions of future events are forward-looking
statements. The words "believe," "expect," "intend," "estimate,"
"anticipate," "will," "could," "should" and similar expressions are
intended to further identify such forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995.
It is important to note that the Company's actual results or
performance could differ materially from those anticipated or
projected in such forward-looking statements. Factors that could
cause Luminex's actual results or performance to differ materially
include risks and uncertainties relating to, among others, market
demand and acceptance of Luminex's products, the Company's
dependence on strategic partners for development, commercialization
and distribution of products, concentration of the Company's
revenue in a limited number of strategic partners, fluctuations in
quarterly results due to a lengthy and unpredictable sales cycle
and bulk purchases of consumables, Luminex's ability to scale
manufacturing operations and manage operating expenses, gross
margins and inventory levels, potential shortages of components,
competition, the timing of regulatory approvals, the
implementation, including any modification, of the Company's
strategic operating plans, risks and uncertainties associated with
implementing our acquisition strategy and the ability to integrate
acquired companies or selected assets into our consolidated
business operations, as well as the risks discussed under the
heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q,
as filed with the Securities and Exchange Commission. The
forward-looking statements contained herein represent the judgment
of Luminex as of the date of this press release, and Luminex
expressly disclaims any intent, obligation or undertaking to
release publicly any updates or revisions to any forward- looking
statements to reflect any change in Luminex's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based. Contact: Harriss T. Currie
Vice President, Finance and Chief Financial Officer 512-219-8020
DATASOURCE: Luminex Corporation CONTACT: Harriss T. Currie, Vice
President, Finance and Chief Financial Officer of Luminex
Corporation, +1-512-219-8020, Web site: http://www.luminexcorp.com/
Copyright
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024